Monica Andreoli

Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models

Sheryl M. Gough, John J. Flanagan, Jessica L.F. Teh et al. · Clinical Cancer Research · 2024 · 160 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer

JJ Flanagan, Yimin Qian, SM Gough et al. · Cancer Research · 2019 · 133 citations

Medicine, Biochemistry, Endocrinology +16

Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer

Lawrence B. Snyder, John J. Flanagan, Yimin Qian et al. · Cancer Research · 2021 · 110 citations

Life Sciences, Biochemistry, Endocrinology +15

Discovery of (<i>R</i>)-2-Amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic Acid and Congeners As Highly Potent Inhibitors of Human Arginases I and II for Treatment of Myocardial Reperfusion Injury

M.C. Van Zandt, Darren L. Whitehouse, Adam Gołȩbiowski et al. · Journal of Medicinal Chemistry · 2013 · 85 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Osteocalcin Production in Primary Osteoblast Cultures Derived from Normal and Hyp Mice

Thomas O. Carpenter, Kathleen Moltz, Bruce Ellis et al. · Endocrinology · 1998 · 61 citations · Full text

Medicine, Cell Biology, Physiology +14